It was a pleasure to discuss with Dr Susan Manzi (Allegheny Health Network Medicine Institute, Pittsburgh, PA, USA) the recent post-hoc analysis designed to assess the efficacy of anifrolumab by baseline therapy.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract entitled ‘SLE Treatment History and Anifrolumab Efficacy by Baseline Standard Therapies in Patients with SLE from 2 Phase 3 Trials’ was presented at the ACR Convergence, 5-9 November 2021.
Questions
- What did the TULIP-1 and TULIP-2 studies teach us about the efficacy and safety of anifrolumab in people with SLE? (0:12)
- What were the objectives of the current post-hoc analysis of the TULIP-1 and TULIP-2 data? (0:56)
- What were the findings across the different therapy subgroups? (1:35)
- Could you tell us a little about the limitations of this study? (2:25)
- What are the clinical implications of these findings? (3:07)
Disclosures: Dr Susan Manzi has acted as an advisor for AstraZeneca; a consultant for Exagen Diagnostics, Inc., Cugene, GlaxoSmithKline and Eli Lilly; an officer/board member for the Lupus Foundation of America; received grant/ research support from AstraZeneca, Merck-Serono, AbbVie and GlaxoSmithKline; received royalties from Exagen Diagnostics and has intellectual properties/ patents with Exagen Diagnostics, University of Pittsburgh and the Allegheny Singer Research Institute.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
